Clinical research study to assess ability of eltrombopag to induce sustained remission in subjects with Immune Thrombocytopenia who are refractory or relapsed after first line steroids TAPER

This research study is to find out if the study drug eltrombopag also known as Revolade/Promacta can help those who have Immune Thrombocytopenia (ITP.)  The study will determine if subjects are able to stop eltrombopag treatment while maintaining acceptable platelet levels after their disease has become resistant to treatment or has a reoccurrence of symptoms after initial treatment with steroids. This study will enroll subjects who are at least 18 years old, have refractory ITP and have failed first line treatments.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Immune Thrombocytopenia
• Age: Between 18 Years - 99 Years
• Gender: All